Results of a Phase 3 study of Amifampridine phosphate (3,4-diaminopyridine) for Lambert-Eaton myasthenia syndrome (LEMS) in Japan - DyDo Pharma, Inc.

Results of a Phase 3 study of Amifampridine phosphate (3,4-diaminopyridine) for Lambert-Eaton myasthenia syndrome (LEMS) in Japan

What's News July 24, 2023

For details, please see the PDF below.
> Results of a Phase 3 study of Amifampridine phosphate (3,4-diaminopyridine) for Lambert-Eaton myasthenia syndrome (LEMS) in Japan（PDF）